Navigation Links
Blocking overactive receptor in Alzheimer's recovers memory loss and more
Date:6/17/2013

This news release is available in French.

A new study shows that memory pathology in older mice with Alzheimer's disease can be reversed with treatment. The study by researchers from the Montreal Neurological Institute and Hospital - The Neuro, at McGill University and at Universit de Montral found that blocking the activity of a specific receptor in the brain of mice with advanced Alzheimer's disease (AD) recovers memory and cerebrovascular function. The results, published in the Journal of Neuroinflammation in May, also suggest an underlying mechanism of AD as a potential target for new therapies.

"The exciting and important aspect of this study is that even animals with advanced pathology can be rescued with this molecule" says Dr. Edith Hamel, neuroscientist at The Neuro and lead investigator on the paper in collaboration with Dr Rjean Couture at the Department of Physiology at Universit de Montral. "We have rarely seen this type of reversal of AD symptoms before in our mouse model at this advanced age when mice have been developing AD for one year."

The researchers found an increased level of a receptor known as bradykinin B1 receptor (B1R) in the brain of mice with AD, a receptor involved in inflammation. "By administering a molecule that selectively blocks the action of this receptor, we observed important improvements in both cognitive and cerebrovascular function," says Dr. Baptiste Lacoste, research fellow who conducted the study at The Neuro and now pursuing his training at Harvard Medical School in Boston. "Alzheimer's disease destroys nerve cells and also compromises the function of blood vessels in the brain. Not only were there improvements in learning and memory, but also marked recovery in blood flow and vascular reactivity, i.e. the ability of cerebral vessels to dilate or constrict when necessary." Proper functioning of blood vessels in the brain is vital to providing nutrients and oxygen to nerve cells, and vascular diseases represent important risk factors for developing AD at an advanced age.

"Another interesting result that has not been seen before in our mouse model is a reduction by over 50% of toxic amyloid-beta peptide," adds Dr. Hamel. "In Alzheimer's disease, protein fragments called amyloid-beta have a deleterious effect on the blood and nervous systems. Normally, these protein fragments are broken down and removed. In Alzheimer's disease, the protein fragments clump together a factor believed to contribute to neuronal and vascular dysfunction. We are not sure if these decreases contribute to the functional recovery, but we hope that our findings will aid in clarifying this issue and identifying new targets for therapeutic approaches."

The results show that an increase in B1R is associated with amyloid-beta plaques in Alzheimer's disease mice with impaired memory, and that chronic blockade of B1R significantly improves learning, memory, cerebrovascular function, and several other pathological AD hallmarks in mice with a fully developed pathology. Together, these findings confirm a role of B1R in AD pathogenesis and the role of neuroinflammation as an underlying mechanism in AD. The next step would be to further investigate potential blockers of the bradykinin B1R as a potential treatment for AD in humans.


'/>"/>

Contact: Anita Kar
514-398-3376
McGill University
Source:Eurekalert

Related biology news :

1. Blocking DNA: HDAC inhibitor targets triple negative breast cancer
2. Drug reduces fat by blocking blood vessels
3. Measuring progesterone receptor expression to improve hormone-receptor-positive cancer management
4. G protein-coupled receptor mediates the action of castor oil
5. BUSM study identifies receptors role in regulating obesity, type 2 diabetes
6. Cell receptor has proclivity for T helper 9 cells, airway inflammation
7. Steroid hormone receptor prefers working alone to shut off immune system genes
8. Jackson Laboratory researchers provide definitive proof for receptors role in synapse development
9. Dopamine-receptor gene variant linked to human longevity
10. How the tilt of a cell-surface receptor prevents cancer
11. Activation of cortical type 2 cannabinoid receptors ameliorates ischemic brain injury
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/9/2017)... Australia , March 9, 2017 4Dx ... prestigious World Lung Imaging Workshop at the University of ... was invited to deliver the latest data to world ... recognised event brings together leaders at the forefront of ... in lung imaging. "The quality of ...
(Date:3/2/2017)... , March 2, 2017 Summary This ... Perrigo and its partnering interests and activities since 2010. ... Read the ... and Alliance since 2010 report provides an in-depth insight into ... sciences companies. On demand company reports are prepared ...
(Date:2/28/2017)... 28, 2017   Acuant , a leading provider ... significant enhancements to new and core technologies building upon ... include mobile and desktop Acuant FRM TM facial ... a real time manual review of identity documents by ... the fastest and most accurate capture software to streamline ...
Breaking Biology News(10 mins):
(Date:3/28/2017)... ... March 28, 2017 , ... Executive ... Officer with Avomeen Analytical Services. Harvill is a distinguished life sciences expert with ... Avomeen is a leader in a wide range of services related to laboratory ...
(Date:3/27/2017)... Cousins Properties (NYSE: CUZ ) announced today that ... a 10-year, approximately 125,000 square-foot lease at Corporate Center, a ... Westshore submarket of Tampa, FL. ... Center for their new location in Tampa ... officer of Cousins Properties. "Amgen is a cutting-edge global company ...
(Date:3/27/2017)... , March 27, 2017  The global ... for 2016, according to a new report from ... lab testing is performed to evaluate disease progression, ... therapy, among other reasons.  The healthcare market research ... , provides an overview of the medical ...
(Date:3/27/2017)... ... , ... PMG Research is pleased to announce its participation in ... Forum in Boston on April 3-4, 2017. The CTC conference focuses on how the ... bring them closer to the patient. Clinical Trial Collaborations also will present an inaugural ...
Breaking Biology Technology: